Cover American Journal of Veterinary Research
American Journal of Veterinary Research
ISSN:
0002-9645
Publication Date:
01 May 2015

  • 1. Sykes JE, Papich MG. Chapter 9: antifungal drugs. In: Sykes JE, ed. Canine and feline infectious diseases. St Louis: Elsevier, 2014; 87–96.

    • Search Google Scholar
    • Export Citation

  • 2. Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50: 2009–2015.

    • Search Google Scholar
    • Export Citation

  • 3. Kim H, Likhari P, Kumari P, et al. High-performance liquid chromatographic analysis of the anti-fungal agent SCH 56592 in dog serum. J Chromatogr B Biomed Sci Appl 2000; 738: 93–98.

    • Search Google Scholar
    • Export Citation

  • 4. Katragkou A, Tsikopoulou F, Roilides E, et al. Posaconazole: when and how? The clinician's view. Mycoses 2012; 55: 110–122.

  • 5. Nomeir AA, Kumari P, Hilbert MJ, et al. Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys. Antimicrob Agents Chemother 2000; 44: 727–731.

    • Search Google Scholar
    • Export Citation

  • 6. Cendejas-Bueno E. HPLC/UV or bioassay: two valid methods for posaconazole quantification in human serum samples. Clin Microbiol Infect 2012; 18: 1229–1235.

    • Search Google Scholar
    • Export Citation

  • 7. United States Pharmacopeia (USP-NF). USP 37-NF 32. General chapter on validation of compendial procedures. Rockville, Md: United States Pharmacopeial Convention, 2014.

    • Search Google Scholar
    • Export Citation

  • 8. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982.

  • 9. Krishna G, Ma L, Martinho M, et al. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J Antimicrob Chemother 2012; 67: 2725–2730.

    • Search Google Scholar
    • Export Citation

  • 10. Courtney R, Pai S, Laughlin M, et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003; 47: 2788–2795.

    • Search Google Scholar
    • Export Citation

  • 11. Posaconazole, Noxafil [package insert]. Whitehouse Station, NJ: Merck & Co Inc, 2014.

  • 12. Ashbee HR, Barnes RA, Johnson EM, et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 2014; 69: 1162–1176.

    • Search Google Scholar
    • Export Citation

  • 13. Jang SH, Colangelo PM, Gobburu JVS. Exposure–response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther 2010; 88: 115–119.

    • Search Google Scholar
    • Export Citation

  • 14. Sun H, Su X, Shi Y. Current status of in vitro and in vivo antifungal activities of posaconazole. J Transl Intern Med 2013; 1: 18–22.

    • Search Google Scholar
    • Export Citation

  • 15. Toutain PL, Bousquet-Mélou A. Bioavailability and its assessment. J Vet Pharmacol Ther 2004; 27: 455–466.

  • 16. Toutain PL, Bousquet-Mélou A. Plasma terminal half-life. J Vet Pharmacol Ther 2004; 27: 427–439.

Advertisement

Editorial Type:
Pharmacology

Posaconazole pharmacokinetics after administration of an intravenous solution, oral suspension, and delayed-release tablet to dogs

Jennifer Kendall BS1 and Mark G. Papich DVM, MS2
View More View Less
  • 1 Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27607.
  • | 2 Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27607.
DOI:
https://doi.org/10.2460/ajvr.76.5.454
Volume/Issue:
Volume 76: Issue 5
Online Publication Date:
01 May 2015
Restricted access
Reprints and Permissions Purchase Article

Abstract

OBJECTIVE To determine pharmacokinetics of posaconazole in dogs given an IV solution, oral suspension, and delayed-release tablet.

ANIMALS 6 healthy dogs.

PROCEDURES Posaconazole was administered IV (3 mg/kg) and as an oral suspension (6 mg/kg) to dogs in a randomized crossover study. Blood samples were collected before (time 0) and for 48 hours after each dose. In an additional experiment, 5 of the dogs received posaconazole delayed-release tablets (mean dose, 6.9 mg/kg); blood samples were collected for 96 hours. Plasma concentrations were analyzed with high-performance liquid chromatography.

RESULTS IV solution terminal half-life (t1/2) was 29 hours (coefficient of variation [CV], 23%). Clearance and volume of distribution were 78 mL/h/kg (CV, 59%) and 3.3 L/kg (CV, 38%), respectively. Oral suspension t1/2 was 24 hours (CV, 42%). Maximum plasma concentration (Cmax) of 0.42 μg/mL (CV, 56%) was obtained at 7.7 hours (CV, 92%). Mean bioavailability was 26% (range, 7.8% to 160%). Delayed-release tablet t1/2 was 42 hours (CV, 25%), with a Cmax of 1.8 μg/mL (CV, 44%) at 9.5 hours (CV, 85%). Mean bioavailability of tablets was 159% (range, 85% to 500%). Bioavailability of delayed-release tablets was 497% (range, 140% to 1,800%) relative to that of the oral suspension.

CONCLUSIONS AND CLINICAL RELEVANCE Absorption of posaconazole oral suspension in dogs was variable. Absorption of the delayed-release tablets was greater than absorption of the oral suspension, with a longer t1/2 that may favor its clinical use in dogs. Administration of delayed-release tablets at a dosage of 5 mg/kg every other day can be considered for future studies.

Contributor Notes

Address correspondence to Dr. Papich (mgpapich@ncsu.edu).